Aging Demographics And Rising Occupancy Rates Will Support A Long-Term Recovery Narrative

Catalysts

About emeis Société anonyme

emeis Société anonyme operates nursing homes and healthcare facilities across Europe, focusing on long term elderly care and clinical services.

What are the underlying business or industry changes driving this perspective?

• Progressive normalization of occupancy rates in key markets like France and Germany, supported by rising care needs as populations age, is expected to support mid single digit revenue growth and reinforce operating leverage, which in turn may lift EBITDA and EBIT over time.
• Greater pricing power as facilities move closer to mature occupancy levels and quality improvements are recognized by regulators and residents could enhance average daily rates and contribute to an expansion in EBITDA margin and net income.
• Demographic driven growth in demand for long term care capacity across Europe, combined with limited public sector supply, positions emeis to selectively ramp up existing sites and pursue new asset light developments, in line with a 4 to 5 percent annual revenue growth target and an ambition for double digit EBITDA CAGR.
• A structural shift to more disciplined, lower intensity development CapEx and partnership based real estate solutions may reduce capital intensity and interest costs, which could improve free cash flow generation and support deleveraging and earnings growth.
• A real estate partnership and disposal program that seeks to materially reduce net debt while preserving operational control of assets is intended to lower the leverage ratio, reduce financial expenses and potentially support equity value creation through higher net margins and earnings per share.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming emeis Société anonyme's revenue will grow by 4.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from -5.1% today to 0.8% in 3 years time.
• Analysts expect earnings to reach €49.0 million (and earnings per share of €0.25) by about December 2028, up from €-292.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €96.5 million in earnings, and the most bearish expecting €-74.9 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 58.1x on those 2028 earnings, up from -7.7x today. This future PE is greater than the current PE for the GB Healthcare industry at 35.6x.
• Analysts expect the number of shares outstanding to grow by 0.16% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.76%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Execution risk in the turnaround remains high. If emeis fails to sustain occupancy gains near 88% on the mature perimeter or if the expected recovery in underperforming units stalls, revenue growth could fall short of the guided 4 to 5 percent per year and operating leverage would weaken, putting pressure on EBITDA and net income.
• The business model is increasingly tied to real estate partnerships and large disposal programs. If property valuations in European healthcare real estate remain subdued for longer or fall further instead of recovering as management expects, this would limit upside from the new vehicle, slow deleveraging and keep interest expenses elevated, constraining earnings and free cash flow.
• Political and regulatory scrutiny of private elderly care remains intense, exemplified by recent media investigations in Ireland and ongoing debates in France about the legitimacy of the private sector. Tighter staffing rules, price caps or sanction driven admissions freezes would raise staff costs and limit pricing power, compressing margins and delaying the return to positive net income.
• The strategy assumes sustained demographic tailwinds and growing long term care needs across Europe. If public sector or nonprofit providers expand capacity faster than expected or governments shift funding away from private operators amid political pressure, emeis could lose share and face slower ramp up of new and existing facilities, dampening revenue growth and EBITDA expansion.
• The balance sheet, while improving, remains heavily leveraged even after disposals, with pro forma net debt of about EUR 3.8 billion and a leverage ratio still around 13 times. Any slowdown in EBITDA growth from the targeted 12 to 16 percent or a rise in funding costs could quickly erode coverage ratios, limiting strategic flexibility and weighing on net income and equity value.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of €13.28 for emeis Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €17.5, and the most bearish reporting a price target of just €7.9.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be €6.5 billion, earnings will come to €49.0 million, and it would be trading on a PE ratio of 58.1x, assuming you use a discount rate of 9.8%.
  
• Given the current share price of €13.93, the analyst price target of €13.28 is 4.9% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.